hERG Inhibitors
1 drugsAbout hERG
The human Ether-à-go-go-Related Gene (hERG), also known as KCNH2, encodes a potassium ion channel crucial for cardiac repolarization. This channel regulates the heart's electrical activity, allowing the heart muscle to reset between beats.
hERG is a critical target in drug development for assessing cardiotoxicity. Blocking the hERG channel can prolong the QT interval, potentially leading to Torsades de Pointes. There is no genetic evidence data available for this target.
hERG is targeted by one FDA-approved drug, RANOLAZINE, a small molecule. I3 PHARMS is the only company with an approved drug targeting hERG.
Strategic Insights
ℹ️ How we calculate- White space opportunity in STEMI (ST Elevation MI) with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top hERG Drugs
I3 PHARMS is the only company with an approved drug targeting hERG.
Low market concentration indicates a potential opportunity for new entrants, but also high barriers to entry.
hERG Clinical Trials 56 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 8 | 0 | 0 | 100% |
| Phase 2 | 22 | 12 | 7 | 3 | 63% |
| Phase 3 | 10 | 8 | 2 | 0 | 80% |
| Phase 4 | 16 | 10 | 6 | 0 | 63% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 19 clinical trials targeting hERG.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities